160 related articles for article (PubMed ID: 16709850)
1. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41.
Cole AL; Yang OO; Warren AD; Waring AJ; Lehrer RI; Cole AM
J Immunol; 2006 Jun; 176(11):6900-5. PubMed ID: 16709850
[TBL] [Abstract][Full Text] [Related]
2. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
Fuhrman CA; Warren AD; Waring AJ; Dutz SM; Sharma S; Lehrer RI; Cole AL; Cole AM
FEBS J; 2007 Dec; 274(24):6477-87. PubMed ID: 18028423
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
4. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.
Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD
J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458
[TBL] [Abstract][Full Text] [Related]
5. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
6. Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction.
Sen J; Yan T; Wang J; Rong L; Tao L; Caffrey M
Biochemistry; 2010 Jun; 49(24):5057-65. PubMed ID: 20481578
[TBL] [Abstract][Full Text] [Related]
7. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.
Gallo SA; Wang W; Rawat SS; Jung G; Waring AJ; Cole AM; Lu H; Yan X; Daly NL; Craik DJ; Jiang S; Lehrer RI; Blumenthal R
J Biol Chem; 2006 Jul; 281(27):18787-92. PubMed ID: 16648135
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
9. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
10. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.
Owen SM; Rudolph DL; Wang W; Cole AM; Waring AJ; Lal RB; Lehrer RI
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1157-65. PubMed ID: 15588337
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
12. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
[TBL] [Abstract][Full Text] [Related]
13. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
15. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
16. Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.
Pacheco B; Alsahafi N; Debbeche O; Prévost J; Ding S; Chapleau JP; Herschhorn A; Madani N; Princiotto A; Melillo B; Gu C; Zeng X; Mao Y; Smith AB; Sodroski J; Finzi A
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003492
[TBL] [Abstract][Full Text] [Related]
17. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.
Ni L; Gao GF; Tien P
Biochem Biophys Res Commun; 2005 Jul; 332(3):831-6. PubMed ID: 15913557
[TBL] [Abstract][Full Text] [Related]
18. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
Cunyat F; Marfil S; García E; Svicher V; Pérez-Alvárez N; Curriu M; Perno CF; Clotet B; Blanco J; Cabrera C
Retrovirology; 2012 Feb; 9():15. PubMed ID: 22333046
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antiviral Res; 2003 Jul; 59(2):137-42. PubMed ID: 12895697
[TBL] [Abstract][Full Text] [Related]
20. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
